(Reuters) - Cubist Pharmaceuticals Inc said its experimental antibiotic for treating abdominal infections was found as effective as a widely used antibiotic in a late-stage trial. Cubist's drug, a combination of ceftolozane and tazobactam, was being tested in patients with complicated intra-abdominal infections, in combination with another antibiotic, metronidazole. The data comes close on the heels of positive results from another late-stage study last month that showed the drug was successful in treating urinary tract infection. Based on the success of the two trials, Cubist said it expected to submit for U.S. regulatory approval of the drug in the first half of 2014 for use in both infections.
via Health News Headlines - Yahoo News http://news.yahoo.com/cubist-antibiotic-succeeds-stage-trial-shares-rise-131248120--finance.html
No comments:
Post a Comment